Overview

A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
0
Participant gender:
All
Summary
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week treatment.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Criteria
Inclusion Criteria:

- Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on
beta-blocker monotherapy or dual therapy in which at least one medication is a
beta-blocker for at least 4 weeks prior to screening

Exclusion Criteria:

- Closed/ barely open anterior chamber angle or history of acute angle closure glaucoma.

- History of ALT (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months
prior to screening